Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 3/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ACP1 | P24666 | 1/20 | 0.40 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28085685 | 0.98 | SRC (0.64) | SRCCYP2D6LMNAMAPK1CYP2C19 | |
| SCHEMBL27829711 | 0.85 | SRC (0.53) | SRCCYP2D6LMNAMAPK1CYP2C19 | |
| SCHEMBL3514146 | 0.83 | SRC (0.52) | SRCCYP2D6LMNAMAPK1CYP2C19 | |
| SCHEMBL27467301 | 0.83 | SRC (0.52) | SRCCYP2D6LMNAMAPK1CYP2C19 | |
| SCHEMBL8032594 | 0.82 | SRC (0.47) | SRCCYP2D6LMNACYP2C19KMT2A | |
| Hydrochloric Acid SCHEMBL6647673 | 0.82 | SRC (0.50) | SRCCYP2D6LMNAMAPK1CYP2C19 | |
| SCHEMBL28566434 | 0.80 | KMT2A (0.58) | SRCLMNAKMT2APTGS2ALDH1A1 | |
| SCHEMBL9912818 | 0.80 | SRC (1.00) | SRCCYP2D6LMNAMAPK1CYP2C19 | |
| SCHEMBL20869602 | 0.80 | SRC (1.00) | SRCCYP2D6LMNAMAPK1CYP2C19 | |
| SCHEMBL11166146 | 0.80 | SRC (1.00) | SRCCYP2D6LMNAMAPK1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2551265-B2 | Novel process for the preparation of 1-(6-methylpyridin-3-yl)-2-[4-(methylsulfonyl)phenyl]ethanone, an intermediate of etoricoxib. | F I S - FABBRICA ITALIANA SINTETICI S P A (IT) | 2017-09-13 | — | — | EP | claimed |
| CN-102898357-B | For preparing the new method of intermediate 1-(6-picoline-3-base)-2-[4-(mesyl) phenyl] ethyl ketone of Etoricoxib | 意大利合成制造有限公司 | 2016-07-06 | — | — | CN | claimed |
| EP-2551265-B1 | Novel process for the preparation of 1-(6-methylpyridin-3-yl)-2-[4-(methylsulfonyl)phenyl]ethanone, an intermediate of etoricoxib. | ITALIANA SINT SPA (IT) | 2015-01-07 | — | — | EP | claimed |
| EP-2551265-A1 | Novel process for the preparation of 1-(6-methylpyridin-3-yl)-2-[4-(methylsulfonyl)phenyl]ethanone, an intermediate of etoricoxib. | F.I.S.- Fabbrica Italiana Sintetici S.p.A. (IT) | 2013-01-30 | — | — | EP | claimed |
| CN-113666853-B | Biaryl compounds useful as ROR gamma modulators | 上海辉启生物医药科技有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-112851557-B | Sulfo-substituted biaryl compound or salt thereof, and preparation method and application thereof | 上海辉启生物医药科技有限公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-114502532-A | Sulfo-substituted biaryl compound or salt thereof, and preparation method and application thereof | 上海辉启生物医药科技有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-112851557-A | Sulfo-substituted biaryl compound or salt thereof, and preparation method and application thereof | 上海辉启生物医药科技有限公司 | 2021-05-28 | — | — | CN | disclosed |
| CN-104961674-B | Preparation method for the reference substance for synthesizing Etoricoxib | 湖南方盛制药股份有限公司 | 2018-08-17 | — | — | CN | disclosed |
| EP-2551265-B2 | Novel process for the preparation of 1-(6-methylpyridin-3-yl)-2-[4-(methylsulfonyl)phenyl]ethanone, an intermediate of etoricoxib. | F I S - FABBRICA ITALIANA SINTETICI S P A (IT) | 2017-09-13 | — | — | EP | disclosed |
| CN-104045596-B | Method for preparing etoricoxib intermediate 1-(6-methylpyridyl-3-yl)-2-[4-(mesyl)-phenyl]-ethyl-one | 成都克莱蒙医药科技有限公司 | 2017-03-22 | — | — | CN | disclosed |
| CN-102898357-B | For preparing the new method of intermediate 1-(6-picoline-3-base)-2-[4-(mesyl) phenyl] ethyl ketone of Etoricoxib | 意大利合成制造有限公司 | 2016-07-06 | — | — | CN | disclosed |
| EP-2551265-B1 | Novel process for the preparation of 1-(6-methylpyridin-3-yl)-2-[4-(methylsulfonyl)phenyl]ethanone, an intermediate of etoricoxib. | ITALIANA SINT SPA (IT) | 2015-01-07 | — | — | EP | disclosed |
| EP-2551265-A1 | Novel process for the preparation of 1-(6-methylpyridin-3-yl)-2-[4-(methylsulfonyl)phenyl]ethanone, an intermediate of etoricoxib. | F.I.S.- Fabbrica Italiana Sintetici S.p.A. (IT) | 2013-01-30 | — | — | EP | disclosed |
| CN-102898357-A | Novel process for the preparation of 1-(6-methylpyridin-3-yl)-2-[4-(methylsulfonyl)phenyl]ethanone, an intermediate of etoricoxib. | ITALIANA SINT SPA | 2013-01-30 | — | — | CN | disclosed |
| US-20130023526-A1 | Isoxazolines as Therapeutic Agents | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| EP-1558607-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004041813-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-05-21 | — | — | WO | disclosed |
| EP-1163214-A1 | GAMMA-KETOACID DIPEPTIDES AS INHIBITORS OF CASPASE-3 | Merck Frosst Canada & Co. (CA) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000055127-A1 | GAMMA-KETOACID DIPEPTIDES AS INHIBITORS OF CASPASE-3 | MERCK FROSST CANADA & CO. (CA) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023526-A1 | Isoxazolines as Therapeutic Agents | CYP3A7, CYP11B2, CYP11B1 | SRC 3856/4885CYP2D6 37/4885LMNA 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.